-
Mashup Score: 2
Novartis has received US Food and Drug Administration (FDA) approval to begin supplying Pluvicto for US commercial use from the Novartis Radioligand Therapy (RLT) manufacturing facility in Millburn, New Jersey.
Source: NovartisCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LR Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Source: NovartisCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LR Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Source: NovartisCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LR Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Source: NovartisCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 8
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LR Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Source: NovartisCategories: Hem/Oncs, Latest HeadlinesTweet-
⭐️The NATALEE ( Press release data) is positive👉 Ribociclib plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting. 👉NATALEE is the first and only positive Phase III study https://t.co/RwRN1V9MGt… https://t.co/0GhZ1XBlXE
-
-
Mashup Score: 8
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LR Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Source: NovartisCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Children in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years post one-time intravenous infusionAll children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walkingTo date, more than 3,000 children with spinal muscular atrophy have been treated with Zolgensma…
Source: NovartisCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 11
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LR Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Source: NovartisCategories: Latest Headlines, Oncologists2Tweet-
Novartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer | Novartis https://t.co/jtwvB9mDfI
-
-
Mashup Score: 10
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LR Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Source: NovartisCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LR Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Source: NovartisCategories: Hem/Oncs, Latest HeadlinesTweet
On April 21, Novartis announced that they received approval by the FDA to begin supplying Pluvicto for U.S. commercial use from their manufacturing facility in Millburn, NJ. Read the announcement here: https://t.co/0dmk8sXVmc https://t.co/zlFBiS5uoM